NewsAugust 1, 2023
LSI Medience Begins Contract Testing Service for GenMineTOP® Cancer Genome Profiling System
LSI Medience Corporation (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director: Haruo Watanabe) announces an executed contract reflecting an agreement with Konica Minolta REALM, Inc. (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director: Junji Tashiro, hereafter Konica Minolta REALM) to provide contract testing for the GenMineTOP® Cancer Genome Profiling System. Konica Minolta REALM began sales and contract testing services with medical institutions from August 1, 2023. For more information, please see the announcement made by Konica Minolta, Inc.
- For details on the contract testing:
www.medience.co.jp/clinical/information/ (only in Japanese)
- Announcement made by Konica Minolta, Inc.:
www.konicaminolta.com/jp-ja/newsroom/2023/0801-01-01.html (only in Japanese)
About LSI Medience
Established in 1975, LSI Medience Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523). It is dedicated to business across clinical testing, diagnostic reagents and instruments, and drug development support, and creates new solutions based on core analytical capabilities accumulated over the years in diverse testing services. LSI Medience Corporation contributes to the prevention, early detection, and treatment of diseases, as well as engage in supporting development of next-generation medical care, such as personalized medicine.